CMS Open Payments · Program Year 2024
Smaio USA Corporation
Smaio USA Corporation reported $12,215.34 across General Payments, Research, and Ownership to 46 physicians and teaching hospitals across 46 transactions.
- $12.2K
- All-tracks total
- 46
- Transactions
- 46
- Recipients
- #1613
- of 1,925 companies
Smaio USA Corporation reported $12,215.34 across all CMS Open Payments tracks (General + Research + Ownership) to 46 physicians and teaching hospitals in Program Year 2024 - ranking #1613 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $12,215.34, averaging $265.55 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer smaio-usa-corporation Smaio USA Corporation
$12.2K · #1613/1,925 · 0.0% industry · PY2024
- TOT $12.2K
- RANK #1613
- SHARE 0.0%
- TXN 46
- RCP 46
- CAT 2
- GEN $12.2K
- TOP1 10.4%
- PY 2024
Volume peers
Nearest volume peer: Validus Pharmaceuticals LLC ($12.3K)
Smaio USA Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Smaio USA Corporation
Rank #1613 of 1,925 companies in CMS Open Payments for 2024 belongs to Smaio USA Corporation, which reported $12,215.34 across 46 transactions to 46 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $265.55 per transaction and $265.55 per recipient.
37 transactions worth $6.2K make "Food and Beverage" the top general-payment category in the 2-category breakdown below, 50.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Smaio USA Corporation's 2-category general-payment breakdown at $6.2K, 50.5% of the reported total.
How Smaio USA Corporation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $6.2K | 37 | 50.5% |
| Travel and Lodging | $6.1K | 9 | 49.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $5,659.59 (46.3%) of $12,215.34 in this company's General Payments records across 27 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Smaio USA Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Neel Anand
$1,274.42 across 3 reported transactions
- 2
Robert K Eastlack
$1,240.72 across 3 reported transactions
- 3
John Christopher Quinn
$1,048.15 across 2 reported transactions
- 4
Mena Kerolus
$1,048.15 across 2 reported transactions
- 5
Taryn Elizabeth Leroy
$1,048.15 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Smaio USA Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Smaio USA Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Smaio USA Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Dutch Ophthalmic Research Center (International) B.V.
Sentec, Inc.
Cytyc Surgical Products, LLC
Astellas Pharma Europe BV
Blue Surgical Llc
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.